These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16305421)

  • 21. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
    Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs.
    Junghanns JU; Buttle I; Müller RH; Araújo IB; Silva AK; Egito ES; Damasceno BP
    Pharm Dev Technol; 2007; 12(5):437-45. PubMed ID: 17963143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells.
    Staedtke V; Brähler M; Müller A; Georgieva R; Bauer S; Sternberg N; Voigt A; Lemke A; Keck C; Möschwitzer J; Bäumler H
    Small; 2010 Jan; 6(1):96-103. PubMed ID: 19882684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS).
    Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Methyl-N-D-fructosyl amphotericin B methyl ester (MF-AME), a novel antifungal agent of low toxicity: monomer/micelle control over selective toxicity.
    Cybulska B; Gadomska I; Mazerski J; Borowski JGE ; Cheron M; Bolard J
    Acta Biochim Pol; 2000; 47(1):121-31. PubMed ID: 10961685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
    Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
    Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
    J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes.
    Clemons KV; Ranney DF; Stevens DA
    Curr Opin Investig Drugs; 2001 Apr; 2(4):480-7. PubMed ID: 11566003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.
    Krause HJ; Juliano RL
    Mol Pharmacol; 1988 Sep; 34(3):286-97. PubMed ID: 3419424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations.
    Jullien S; Brajtburg J; Bolard J
    Biochim Biophys Acta; 1990 Jan; 1021(1):39-45. PubMed ID: 2403812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential.
    Egito LC; de Medeiros SR; Medeiros MG; Price JC; Egito ES
    J Pharm Sci; 2004 Jun; 93(6):1557-65. PubMed ID: 15124213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
    Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
    J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.
    Brime B; Molero G; Frutos P; Frutos G
    Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An effect of antibiotic amphotericin B on ion transport across model lipid membranes and tonoplast membranes.
    Hereć M; Dziubińska H; Trebacz K; Morzycki JW; Gruszecki WI
    Biochem Pharmacol; 2005 Sep; 70(5):668-75. PubMed ID: 16023082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.